OncoMatch/Clinical Trials/NCT05926765
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Is NCT05926765 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for grade 2 and 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract, excluding the parotid glands.
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: beam radiation therapy — head and neck cancer
Completed beam radiation therapy for head and neck cancer at least 3 years prior to the first screening visit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- City of Hope · Duarte, California
- Miami Cancer Institute at Baptist Health South Florida · Miami, Florida
- University of Iowa · Iowa City, Iowa
- Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05926765 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received beam radiation therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify